CPhI Online

- Market News

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Catalent is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.

The new 24,257-sq ft facility will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials. Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.

Located less than a mile from the company’s West Coast early-phase oral drug product development center of excellence, the new facility enhances Catalent’s OptiForm Total Supply service, offering customers fully integrated development, clinical supply manufacturing and distribution. This integrated approach helps customers minimize overall project risks and can significantly reduce the time taken to move a program from development into clinic.

“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the US and Canada’s drug development region.”

With sites in the US, UK, Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and so help to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.

Catalent’s existing San Diego facility is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being in Somerset, New Jersey and Nottingham, UK.